Stryker Co. (NYSE:SYK) Shares Purchased by Fiera Capital Corp

Fiera Capital Corp lifted its holdings in Stryker Co. (NYSE:SYK) by 42.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,713 shares of the medical technology company’s stock after acquiring an additional 4,948 shares during the period. Fiera Capital Corp’s holdings in Stryker were worth $5,687,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in SYK. Burkett Financial Services LLC acquired a new stake in Stryker in the 4th quarter valued at $25,000. Central Pacific Bank Trust Division acquired a new stake in shares of Stryker in the first quarter valued at about $39,000. DSM Capital Partners LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $34,000. Private Wealth Management Group LLC acquired a new position in Stryker during the 4th quarter worth approximately $40,000. Finally, Advantage Trust Co acquired a new stake in Stryker in the fourth quarter valued at approximately $60,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.2 %

Shares of Stryker stock opened at $359.55 on Wednesday. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $362.25. The stock has a 50-day moving average price of $337.95 and a 200 day moving average price of $341.67. The company has a market cap of $136.97 billion, a P/E ratio of 41.04, a P/E/G ratio of 2.78 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The firm had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the prior year, the firm earned $2.54 EPS. The business’s revenue was up 8.5% on a year-over-year basis. As a group, analysts expect that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is 36.53%.

Analyst Ratings Changes

Several research analysts have recently weighed in on SYK shares. The Goldman Sachs Group started coverage on shares of Stryker in a research note on Thursday, May 30th. They issued a “neutral” rating and a $372.00 target price for the company. UBS Group upped their price objective on shares of Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. BTIG Research lifted their target price on Stryker from $360.00 to $374.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Barclays increased their price target on Stryker from $374.00 to $402.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $373.84.

Insiders Place Their Bets

In other news, insider Viju Menon sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Viju Menon sold 600 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares in the company, valued at $3,219,495. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now directly owns 2,852 shares in the company, valued at approximately $949,716. The disclosure for this sale can be found here. Insiders have sold a total of 210,600 shares of company stock valued at $68,330,400 in the last 90 days. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.